Alzamend Neuro(ALZN) - 2024 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended April 30, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF For the transition period from _______________ to _______________ Commission file number 001-40483 ALZAMEND NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 81-1822909 (State or other juris ...